Post-randomization diabetes-related adverse event or the use of antihyperglycaemic medication (insulin or oral treatment) recorded on at least one follow-up visit form for a person without evidence of diabetes mellitus at baseline. This evidence concerns the gene INS and diabetes mellitus.